MedTrace Logo

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

NCT02912572 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2025-07-10

Study results available
· View outcomes & findings →

Summary

This research study is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial cancer.

Conditions

  • Metastatic Endometrial Cancer

Interventions

DRUG

Avelumab

Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment

DRUG

Talazoparib

Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days

DRUG

Axitinib

Axitinib will be taken twice per day by mouth Each Cycle lasts 28 days

Sponsors & Collaborators

Principal Investigators

  • Panagiotis Konstantinopoulos, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-14
Primary Completion
2023-11-15
Completion
2026-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02912572 on ClinicalTrials.gov